Drug Profile
Brimonidine ophthalmic suspension - Sun Pharma Advanced Research Company
Alternative Names: 0.35% brimonidine tartrate; PDP 716Latest Information Update: 21 Jul 2023
Price :
$50
*
At a glance
- Originator Sun Pharma Advanced Research Company
- Class Antiglaucomas; Antihypertensives; Bromobenzenes; Diamines; Eye disorder therapies; Imidazoles; Quinoxalines; Skin disorder therapies; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Glaucoma; Ocular hypertension
Most Recent Events
- 19 Jul 2023 Visiox Pharma announces intention to launch brimonidine ophthalmic suspension for Glaucoma in early 2025
- 08 Dec 2022 FDA assigns PDUFA action date of 04/08/2023 for brimonidine ophthalmic suspension for Glaucoma
- 08 Dec 2022 US FDA accepts NDA for brimonidine ophthalmic suspension for Glaucoma for filing